Shanghai, China – July 27th, 2018 . Curon Biopharmaceutical, a Shanghai-based biopharma company developing next generation cancer immuno-therapies, today announced the completion of a $150 million USD Series A financing. 6 Dimensions Capital, Boyu Capital, and Temasek participated in this round.
July 16th 2018, Shanghai, China. Lyvgen Biopharma, a biotechnology company developing novel immunotherapies based in Shanghai, today announced the completion of a USD $30 million Series B funding round. 6 Dimensions Capital led this round of financing, with participation from Winfair Global, Runling Capital and existing Series A investor Morningside Ventures.
BOSTON--(BUSINESS WIRE)-- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced that the first patient has been dosed in its Phase 3 VICTORY-1 clinical trial of CNTX-4975, a synthetic, ultra-pure injection of trans-capsaicin, for the treatment of chronic moderate to severe pain due to knee osteoarthritis (OA). CNTX-4975 is a highly differentiated, novel, non-opioid therapy that is designed to be injected directly into the painful joint to potentially provide fast-acting and long-lasting pain relief without the risk of abuse and addiction. CNTX-4975 was recently granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe pain associated with knee OA.
6 Dimensions Capital together with Metronic China Ventures,Sequoia Capital China and Suzhou Biobay will organize a China medtech focused forum to present China market opportunities and how to make an entry to China...
December 7, 2017, Shanghai, Boston, Hong Kong, San Francisco. 6 Dimensions Capital announces today the final close of its inaugural US dollar fund & RMB fund at US$533 million and RMB2.06 billion respectively...
(6th Apr 2017, Shanghai, China and San Francisco, US) Frontline today announced Mr. Norman Chen, a venture capitalist and serial entrepreneur in the life sciences and healthcare space to join as Venture Partner. Mr. Chen will be based in the firm’s Silicon Valley office...
(1st March 2017, Shanghai) Frontline BioVentures announced the final close of its RMB Fund II fundraising, which was beyond the target level and increased the fund manager’s total AUM to RMB 3Bn...
Forerunner Medical (Shanghai) Co., Ltd. has announced the completion of the acquisition of Shanghai Medsphere Co., Ltd. In addition, the Medtronic-Sequoia China Healthcare Technology Venture Investment Fund (“Medtronic-Sequoia China) has...